Gilead Sciences, Inc. earnings overview

GILD FY2026 Q1 · Calendar Q2 2026

Gilead Sciences, Inc.

Gilead delivered a solid Q1 2026 beat driven by 10% HIV growth and accelerating Yes2Go adoption, raising full-year revenue guidance by $400 million. Despite the beat, the stock sold off with a -2.9% abnormal move and continued downside drift, suggesting the market had already priced in the positive trajectory. The multi-franchise strategy spans HIV, oncology, liver disease, and cell therapy, with key FDA decisions on Biclen (August 2026), anitocel (December 2026), and Hepcludex (this quarter) as near-term catalysts. The Arcellx and Tubulis acquisitions bolster the ADC and CAR-T pipeline but add integration risk. With the stock at $133.83 versus a consensus target of $159.22, the bullish thesis depends on Yes2Go reaching its $1 billion target, successful Trodelvy label expansions, and clean regulatory execution across multiple pending decisions.